314 related articles for article (PubMed ID: 15266014)
1. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
3. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
4. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
7. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
Suessbrich H; Schönherr R; Heinemann SH; Lang F; Busch AE
FEBS Lett; 1997 Sep; 414(2):435-8. PubMed ID: 9315735
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency.
Ishii K; Nagai M; Takahashi M; Endoh M
Cardiovasc Res; 2003 Mar; 57(3):651-9. PubMed ID: 12618227
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
Gessner G; Zacharias M; Bechstedt S; Schönherr R; Heinemann SH
Mol Pharmacol; 2004 May; 65(5):1120-9. PubMed ID: 15102940
[TBL] [Abstract][Full Text] [Related]
12. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
Mitcheson JS; Chen J; Sanguinetti MC
J Gen Physiol; 2000 Mar; 115(3):229-40. PubMed ID: 10694252
[TBL] [Abstract][Full Text] [Related]
13. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS; Curran ME; Keating MT; Sanguinetti MC
Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
15. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
16. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
17. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Chen J; Seebohm G; Sanguinetti MC
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
[TBL] [Abstract][Full Text] [Related]
18. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Ficker E; Obejero-Paz CA; Zhao S; Brown AM
J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
[TBL] [Abstract][Full Text] [Related]
19. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
20. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
